The goal of this clinical trial is to learn if serum biomarkers can better predict worsening of acute kidney injury (AKI) compared to the Furosemide Stress Test (FST) in adult patients with low albumin levels (hypoalbuminemia) admitted to an intensive care unit (ICU). The main questions it aims to answer are: Can serum biomarkers predict progression to severe AKI (stage 3) better than the Furosemide Stress Test in patients with low albumin levels? Is there a relationship between serum biomarkers levels and serum albumin levels in these patients? Researchers will compare serum biomarkers levels and FST results to see which test more accurately identifies patients at risk of developing severe AKI. Participants will: Provide a sample for serum biomarkers measurement at study entry Receive a single intravenous dose of furosemide (a diuretic medication) to assess kidney function Have their urine output monitored for 6 hours after the furosemide dose Be followed for 15 days to track kidney function, need for dialysis, and survival
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
55
Single intravenous bolus of furosemide administered at 1 mg/kg in patients with no prior exposure to loop diuretics within the previous 7 days, or 1.5 mg/kg in those with such prior exposure. Urine output was measured hourly for 6 hours post-administration. Patients producing ≥200 mL at 2 hours were classified as responders; those producing \<200 mL as non-responders. The test was used as a diagnostic tool to assess tubular function, not as a therapeutic intervention.
Single serum biomarkers and NGAL measurement obtained at enrollment from a urine sample collected via Foley catheter. Samples were analyzed using a commercially available immunofluorescence assay (NGAL Fast Test Kit, Getein Biotech, Inc., China), immediately cooled to 4°C, aliquoted, and stored at -80°C until batch analysis. Used as a diagnostic biomarker of tubular injury, independent of albumin-mediated transport, to predict progression to KDIGO stage 3 AKI in patients with hypoalbuminemia.
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, Mexico
Progression to KDIGO Stage 3 Acute Kidney Injury
Proportion of patients who progressed from KDIGO stage 1-2 to stage 3 AKI, assessed by changes in serum creatinine and/or urine output per KDIGO 2012 criteria. Predictive performance evaluated by AUC-ROC for both uNGAL and Furosemide Stress Test.
Time frame: 15 days from enrollment
Need for Renal Replacement Therapy
Proportion of patients requiring initiation of renal replacement therapy (intermittent hemodialysis or continuous renal replacement therapy) during the follow-up period, based on clinical criteria per the treating nephrologist.
Time frame: 15 days from enrollment
15-Day Mortality
All-cause mortality within the first 15 days of enrollment, recorded through medical record review.
Time frame: 15 days from enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.